Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04118153 · ClinicalTrials.gov registry record · Early Phase 1
Early Markers of Disease and Response to Therapy
A Early Phase 1 study of Type 1 Diabetes, sponsored by Sandra Lord, MD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT04118153 is a Early Phase 1 study of Type 1 Diabetes that has completed, run by Sandra Lord, MD. The registered enrollment target is 60 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04118153, a Early Phase 1 study of Type 1 Diabetes, has completed, sponsored by Sandra Lord, MD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to identify early immune markers associated with response to treatment with abatacept in individuals with Type 1 diabetes (T1D). In this open label mechanistic study, participants who were recently diagnosed with T1D (males or females, ages 6-45 and \<7months from T1D diagnosis) will be treated with a short-course of abatacept (weekly subcutaneous injections for 3 months). Participants will undergo baseline and repeated mixed meal tolerance testing (MMTT) to assess disease progression and blood samples will be obtained at frequent intervals to measure changes in immune markers.
Conditions Studied
Interventions
- DRUG Abatacept
Study Locations (2)
Washington
- Benaroya Research Institute - Seattle
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2024-05-24 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04118153
The ClinicalTrials.gov registry entry for NCT04118153 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (93% lower). The listed sponsor is Sandra Lord, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Abatacept is the first listed.
NCT04118153 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Washington, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT04118153 about?
NCT04118153 is a clinical study titled "Early Markers of Disease and Response to Therapy". The purpose of this study is to identify early immune markers associated with response to treatment with abatacept in individuals with Type 1 diabetes (T1D). In this open label mechanistic study, participants who were recently diagnosed with T1D (males or females, ages 6-45 and \<7months from T1D di...
What is the current status of trial NCT04118153?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2021-03-05. Estimated completion is 2024-05-24.
What conditions does trial NCT04118153 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT04118153?
The interventions under investigation include: Abatacept (DRUG).
Who is sponsoring clinical trial NCT04118153?
This trial is sponsored by Sandra Lord, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04118153 being conducted?
This trial has 2 study locations across Washington, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
RECRUITING · Early Phase 1
-
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
RECRUITING · Early Phase 1
-
Effect of C-peptide on Hypoglycemic Counterregulation
RECRUITING · Early Phase 1
-
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
COMPLETED · Early Phase 1
-
Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy
COMPLETED · Early Phase 1
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.